Loading...
XMADATRY
Market cap251mUSD
Dec 20, Last price  
3.17EUR
1D
1.28%
1Q
2.59%
Jan 2017
114.19%
IPO
88.69%
Name

Atrys Health SA

Chart & Performance

D1W1MN
XMAD:ATRY chart
P/E
—
P/S
1.19
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.26%
Rev. gr., 5y
94.22%
Revenues
202m
+7.79%
1,079,2731,018,9041,089,6162,865,8864,560,7566,035,1157,294,14314,836,66731,396,438121,014,000186,994,000201,569,000
Net income
-46m
L+94.26%
681,811336,533320,1981,294,79163,03997,15911,98500-23,197,000-23,468,000-45,590,000
CFO
-1m
L-92.92%
000409,89501,316,73301,083,49804,694,000-15,434,000-1,093,000

Profile

Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
URL
https://www.atryshealth.com/es/
IPO date
Jul 22, 2016
Employees
1,928
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
201,569
7.79%
186,994
54.52%
121,014
285.44%
Cost of revenue
69,789
52,942
36,888
Unusual Expense (Income)
NOPBT
131,780
134,052
84,126
NOPBT Margin
65.38%
71.69%
69.52%
Operating Taxes
(2,941)
(1,225)
(1,685)
Tax Rate
NOPAT
134,721
135,277
85,811
Net income
(45,590)
94.26%
(23,468)
1.17%
(23,197)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
287
82,478
(120)
BB yield
-0.10%
-19.50%
0.02%
Debt
Debt current
64,311
48,255
25,586
Long-term debt
230,396
267,212
221,118
Deferred revenue
6,662
4,982
4,765
Other long-term liabilities
3,675
6,745
5,752
Net debt
252,452
278,684
210,774
Cash flow
Cash from operating activities
(1,093)
(15,434)
4,694
CAPEX
(6,246)
(15,161)
(8,567)
Cash from investing activities
395
(80,586)
(2,449)
Cash from financing activities
8,193
94,773
14,081
FCF
138,915
127,473
27,697
Balance
Cash
42,177
35,844
40,567
Long term investments
78
939
(4,637)
Excess cash
32,177
27,433
29,879
Stockholders' equity
(44,820)
315,074
(22,692)
Invested Capital
599,039
575,155
502,185
ROIC
22.95%
25.11%
25.76%
ROCE
22.35%
20.70%
16.49%
EV
Common stock shares outstanding
75,811
68,204
53,520
Price
3.67
-40.81%
6.20
-38.92%
10.15
14.04%
Market cap
278,225
-34.20%
422,864
-22.16%
543,223
115.56%
EV
618,548
1,121,554
772,301
EBITDA
161,453
164,397
104,914
EV/EBITDA
3.83
6.82
7.36
Interest
33,047
4,006
11,034
Interest/NOPBT
25.08%
2.99%
13.12%